






Advisory group feedback

Funder perspective

Funder of academic studies:

Clinical trials in order to improve patient access to effective & safe treatment

- Patient centric
- Unmet medical need → rare cancers
- Flexible design → limited patient numbers, real world data
- In relation to other treatments → dose, combination, safety
- Help to academics & SMEs to optimal study design
- International consensus on evidence & design



ACT EU MSP

Can we achieve this?

- Foster collaboration (eg regulatory sandboxes)
- Stimulate more international consortia
 - Funders, patients and academics/SMEs
- Patient centric by optimal patient engagement
- Education for patients and academics/SMEs
- Interaction between regulators and academics/SMEs and funders
 - Scientific advice & ATMP specifics
- Sustainable evidence based patient access to optimal treatment







Tegen kanker. **Voor het leven.**